<DOC>
	<DOCNO>NCT00026377</DOCNO>
	<brief_summary>RATIONALE : SU5416 may stop growth cancer stop blood flow tumor . Androgens stimulate growth prostate cancer cell . Hormone therapy use flutamide , bicalutamide , leuprolide , goserelin may fight prostate cancer reduce production androgen . Radiation therapy use high-energy x-rays damage tumor cell . Combining SU5416 , hormone therapy , radiation therapy may kill tumor cell . PURPOSE : Phase I trial study effectiveness SU5416 plus hormone therapy radiation therapy treat patient prostate cancer .</brief_summary>
	<brief_title>SU5416 Plus Hormone Therapy Radiation Therapy Treating Patients With Prostate Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine safety SU5416 combination standard androgen ablation radiotherapy patient intermediate advanced-stage prostate cancer . OUTLINE : This multicenter , dose-escalation study SU5416 . Patients receive oral bicalutamide daily oral flutamide three time daily least 1 month follow leuprolide goserelin subcutaneously monthly four month . Beginning fourth administration leuprolide goserelin , patient undergo radiotherapy 5 day week 7-8 week . Beginning one month radiotherapy continue 1 month radiotherapy , patient receive SU5416 IV 60 minute day 1 4 . Treatment repeat weekly absence disease progression unacceptable toxicity . Cohorts 3-12 patient receive escalate dos SU5416 maximum tolerate dose ( MTD ) determine . The MTD define dose precede least 3 12 patient experience dose-limiting toxicity . Patients follow every 4-6 week 4 month every 8-12 week 8 month . PROJECTED ACCRUAL : A total 3-18 patient accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<mesh_term>Goserelin</mesh_term>
	<mesh_term>Flutamide</mesh_term>
	<mesh_term>Bicalutamide</mesh_term>
	<mesh_term>Semaxinib</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma prostate least 1 follow : Clinical stage T2b great Gleason score least 8 Pretreatment PSA great 15 ng/mL Pelvic and/or periaortic node ( ) positive abdominal/pelvic CT scan Metastatic disease require palliation local symptom No known brain metastasis PATIENT CHARACTERISTICS : Age : Not specify Performance status : ECOG 02 OR Karnofsky 60100 % Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 75,000/mm3 Hepatic : Bilirubin great upper limit normal ( ULN ) AST great 2.5 time ULN Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance great 60 mL/min Cardiovascular : No symptomatic congestive heart failure No cardiac arrhythmia No uncompensated coronary artery disease ECG physical exam No myocardial infarction severe unstable angina within past 6 month No deep venous arterial thrombosis within past 3 month Pulmonary : No pulmonary embolism within past 3 month Other : No concurrent uncontrolled illness No ongoing active infection No diabetes mellitus severe peripheral vascular disease No psychiatric illness social condition would preclude study No prior allergic reaction attribute compound similar chemical biological composition SU5416 Cremophor EL vehicle No prior severe allergic reaction paclitaxel docetaxel PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No concurrent anticancer chemotherapy Endocrine therapy : Prior hormonal therapy duration allow Radiotherapy : No prior pelvic radiotherapy Surgery : No prior prostatectomy Other : No prior nonhormonal systemic therapy prostate cancer No concurrent investigational commercial agent therapy malignancy No concurrent combination antiretroviral therapy HIVpositive patient</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
	<keyword>stage IV prostate cancer</keyword>
</DOC>